[HTML][HTML] Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment
SH Song, S Lee - Investigative and clinical urology, 2023 - ncbi.nlm.nih.gov
Renal cell carcinoma (RCC) displays a wide spectrum of oncological prognosis and clinical
behavior, and is noted for its generally poor outcome in metastatic settings. However, the …
behavior, and is noted for its generally poor outcome in metastatic settings. However, the …
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus …
A Minervini, M Mir, C Cerrato, G Rebez, R Autorino… - 2024 - escholarship.org
BACKGROUND AND OBJECTIVE: The role of cytoreductive nephrectomy (CN) in the
treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the …
treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the …
Impact of cytoreductive nephrectomy (CRN) on overall survival (OS) in metastatic non–clear cell renal cancer (nccRCC).
AA Nelson, A Szabo, D Kilari - 2023 - ascopubs.org
730 Background: Non-clear cell renal cell carcinoma (nccRCC) accounts for 25% of kidney
cancer diagnoses and encompasses a diverse group of kidney tumors with distinct biology …
cancer diagnoses and encompasses a diverse group of kidney tumors with distinct biology …
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.
416 Background: Immunotherapy-based systemic treatment (ST) is the standard of care for
most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive …
most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive …
[引用][C] Kun-peng Li, Si-yu Chen, Chen-yang Wang, Xiao-ran Li and Li Yang
H Dai, S Li, P Pepe, X Li - 2023 - europepmc.org
Purpose: The prognostic impact of cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) in the era of immunotherapy is yet to be determined. The aim of our …
carcinoma (mRCC) in the era of immunotherapy is yet to be determined. The aim of our …
Up-front targeted therapy prior to cytoreductive nephrectomy in treatment-naive patients with metastatic renal cell carcinoma
Reports of spontaneous resolution of pulmonary metastasis after nephrectomy in patients
with metastatic renal cell carcinoma (mRCC) provided the rationale for surgical debulking …
with metastatic renal cell carcinoma (mRCC) provided the rationale for surgical debulking …
Cytoreductive nephrectomy in the era of targeted-and immuno-therapy for metastatic renal cell carcinoma: an elusive issue? A systematic review of the literature
Background The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) in the era of targeted-(TT) and immuno-(IT) therapy remains controversial. Design …
(mRCC) in the era of targeted-(TT) and immuno-(IT) therapy remains controversial. Design …
Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
P Ghatalia, EA Handorf, M Deng, MR Zibelman… - 2021 - ascopubs.org
4582 Background: The role of CN in mRCC was challenged by the results of the CARMENA
trial in the targeted therapy (TT) era. We sought to evaluate the role of both upfront and …
trial in the targeted therapy (TT) era. We sought to evaluate the role of both upfront and …
[HTML][HTML] The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: an evidence-based …
K Li, S Chen, C Wang, X Li, L Yang - Frontiers in Immunology, 2023 - frontiersin.org
Purpose The prognostic impact of cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) in the era of immunotherapy is yet to be determined. The aim of our …
carcinoma (mRCC) in the era of immunotherapy is yet to be determined. The aim of our …
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population.
A Mejean, S Thezenas, C Chevreau, K Bensalah… - 2019 - ascopubs.org
4508 Background: Carmena was a randomized phase III trial, testing the benefit of CN
followed by sunitinib (arm A) vs sunitinib alone (arm B), with stratification by MSKCC risk …
followed by sunitinib (arm A) vs sunitinib alone (arm B), with stratification by MSKCC risk …